Point-of-care cardiac troponin testing in patients with symptoms suggestive of acute coronary syndrome - project protocol
The aim of this health technology assessment (HTA) is to inform decision-making about the appropriate use of point-of-care (POC) cardiac troponin (cTn) testing. Policy questions such as appropriate settings (rural or remote, ambulance, hospital, emergency room), the timing of testing, and population...
| Main Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
June 2015, 2015
|
| Series: | CADTH optimal use report
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The aim of this health technology assessment (HTA) is to inform decision-making about the appropriate use of point-of-care (POC) cardiac troponin (cTn) testing. Policy questions such as appropriate settings (rural or remote, ambulance, hospital, emergency room), the timing of testing, and population suitable for POC cTn testing have been raised in Canadian jurisdictions. This HTA will address these questions by evaluating the diagnostic accuracy, clinical utility, and cost-effectiveness of POC cTn testing in patients presenting with acute coronary syndrome (ACS) |
|---|---|
| Item Description: | "PROSPERO Registration Number: CRD42015023442." |
| Physical Description: | 1 PDF file (20 pages) illustrations |